Skip to content

What qualifies you for Vyvanse? An overview of diagnostic criteria and prescribing guidelines

5 min read

According to the FDA, Vyvanse (lisdexamfetamine) is approved for treating Attention-Deficit/Hyperactivity Disorder (ADHD) and moderate to severe Binge Eating Disorder (BED) in adults. For those considering this medication, understanding what qualifies you for Vyvanse, beyond just the diagnosis, is the critical first step in the treatment process.

Quick Summary

Qualifying for a Vyvanse prescription requires a formal diagnosis of either ADHD or moderate to severe Binge Eating Disorder by a licensed healthcare provider, alongside a comprehensive medical history review to assess cardiac health and other risk factors.

Key Points

  • Diagnosis is Required: A formal diagnosis of either Attention-Deficit/Hyperactivity Disorder (ADHD) or moderate to severe Binge Eating Disorder (BED) is necessary.

  • Assessment by Qualified Provider: Evaluation and prescription must come from a licensed healthcare provider, such as a PCP, psychiatrist, or NP, who is registered with the DEA.

  • Comprehensive Health History: A thorough review of personal and family medical history, especially regarding cardiac health and substance abuse, is mandatory for patient safety.

  • Exclusion Criteria Exist: Certain cardiovascular conditions, psychiatric issues, and other risk factors can prevent or complicate Vyvanse treatment.

  • Ongoing Monitoring is Crucial: Regular follow-up appointments are required for dosage adjustments, symptom monitoring, and to safely continue treatment with this controlled substance.

  • Not for Weight Loss: Vyvanse is not indicated or recommended for weight loss, and its safety for treating obesity has not been established.

In This Article

Understanding Vyvanse: A Central Nervous System Stimulant

Vyvanse is a brand-name prescription medication that belongs to a class of drugs known as central nervous system (CNS) stimulants. The active ingredient is lisdexamfetamine, which is a prodrug. This means it is therapeutically inactive until the body metabolizes it into dextroamphetamine, the active form that affects brain chemicals like dopamine and norepinephrine. This mechanism helps improve focus and reduce impulsivity in individuals with ADHD, and it can help curb binge-eating episodes in adults with BED.

As a Schedule II controlled substance, Vyvanse has a high potential for abuse and dependence, which is why a thorough medical assessment is mandatory before a prescription can be issued. A licensed healthcare provider, registered with the Drug Enforcement Administration (DEA), is required to conduct a complete evaluation to determine if Vyvanse is a safe and appropriate treatment.

Primary Qualifying Conditions for Vyvanse

The U.S. Food and Drug Administration (FDA) has approved Vyvanse for two specific conditions. A formal diagnosis for one of these is the primary requirement for a prescription.

Attention Deficit Hyperactivity Disorder (ADHD)

To qualify for Vyvanse for ADHD, a patient must be at least six years old and meet the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). A healthcare provider will evaluate for a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with daily functioning. This often involves a detailed history of symptoms that have been present since childhood for adults, or comparison of behaviors to those expected for age-matched peers for children. Common symptoms include:

  • Difficulty sustaining attention in tasks or conversations
  • Frequent forgetfulness in daily activities
  • Trouble organizing tasks and activities
  • Fidgeting, restlessness, or excessive talking
  • Impatience and difficulty waiting for one's turn

The diagnostic process for ADHD may involve multiple sessions with a provider and could include questionnaires or psychological testing to confirm the diagnosis.

Moderate to Severe Binge Eating Disorder (BED)

For adults diagnosed with moderate to severe BED, Vyvanse can also be a treatment option. The diagnostic criteria for BED differ significantly from those for ADHD. An adult patient must have recurrent episodes of binge eating, at least once a week for three months, accompanied by a subjective sense of loss of control. These episodes are also associated with at least three of the following behaviors:

  • Eating much more rapidly than normal
  • Eating until feeling uncomfortably full
  • Eating large amounts of food when not physically hungry
  • Eating alone because of embarrassment over the amount of food being consumed
  • Feeling disgusted, depressed, or guilty after overeating

It is crucial to note that Vyvanse is not a treatment for obesity or used for weight loss, and patients with BED do not engage in compensatory behaviors like purging.

The Diagnostic and Assessment Process

Getting a Vyvanse prescription is a multi-step process that focuses on patient safety and appropriateness. It is not simply a matter of asking for the medication.

The Role of a Qualified Healthcare Provider

Several types of healthcare professionals are qualified to diagnose and prescribe Vyvanse, provided they are properly credentialed and registered with the DEA:

  • Primary Care Physician (PCP): Can perform initial screenings and, in many cases, manage treatment.
  • Psychiatrists: Mental health specialists who are experts in conditions like ADHD and BED and often manage medication.
  • Nurse Practitioners (NPs) and Physician Assistants (PAs): Can prescribe controlled substances in most states under certain regulations.

Necessary Medical and Psychiatric History

Before prescribing, a provider must conduct a thorough medical and psychiatric history evaluation. This assessment is critical for identifying potential contraindications or risks. Key areas include:

  • Cardiac Health: Assessment for heart defects, high blood pressure, and a personal or family history of heart problems or sudden death.
  • Psychiatric History: Evaluation for psychosis, mania, bipolar disorder, or a family history of such conditions, as stimulants can exacerbate these issues.
  • Substance Abuse History: Assessment of a patient's or family's history of alcohol or drug abuse due to the high potential for dependence.
  • Kidney Function: Vyvanse may require dose adjustments for patients with renal impairment.

Comparison of Qualifying Criteria for ADHD and BED

To highlight the different pathways to qualifying for Vyvanse, here is a comparison of the criteria for its two FDA-approved indications.

Feature ADHD (Adults & Children $\geq$ 6) Moderate to Severe BED (Adults)
Primary Symptoms Inattention, hyperactivity, impulsivity Recurrent binge eating episodes, loss of control
Diagnostic Standard DSM-5 criteria DSM-5 criteria
Symptom Duration Must be persistent and have been present since childhood (for adults) At least once a week for 3 months
Age Range Adults and children aged 6 and older Adults only
Associated Behaviors Difficulty organizing tasks, forgetfulness, restlessness Eating rapidly, until uncomfortably full, when not hungry
Risk Assessment Includes abuse potential, cardiac and psychiatric history Includes abuse potential, cardiac and psychiatric history

The Path to Prescribing and Treatment

If a healthcare provider determines that a patient meets the diagnostic criteria and is a suitable candidate, the following steps are typically taken:

  • Initial Prescription: The provider will determine an appropriate starting dose of Vyvanse to be taken in the morning.
  • Monitoring and Titration: The patient is monitored regularly to assess the medication's effectiveness and tolerability. The dose may be adjusted until an optimal dose is reached.
  • Total Treatment Program: For ADHD, Vyvanse is often part of a broader treatment plan that includes counseling, educational support, and other therapies.
  • Ongoing Prescriptions: As a controlled substance, Vyvanse prescriptions cannot be refilled automatically. A new prescription, often with a required visit to the provider, is necessary each month to ensure continued safety and monitoring.

Important Considerations and Contraindications

Not everyone with ADHD or BED will be eligible for Vyvanse due to safety concerns. Certain pre-existing conditions can either make Vyvanse unsafe or require careful monitoring.

  • Cardiovascular Conditions: Patients with known structural cardiac abnormalities, serious heart arrhythmias, or coronary artery disease should avoid Vyvanse. Regular monitoring of blood pressure and heart rate is necessary.
  • Psychiatric Risks: Vyvanse can cause psychotic or manic symptoms, particularly in those with a predisposition to such conditions. A provider will evaluate for bipolar disorder and other psychiatric issues before prescribing.
  • Risk of Abuse and Dependence: The potential for abuse necessitates a careful assessment of a patient's history. The FDA requires a boxed warning to alert providers and patients to this risk.
  • Drug Interactions: Medications like monoamine oxidase inhibitors (MAOIs) should not be taken with Vyvanse. Other medications may also require dose adjustments.
  • Pregnancy and Breastfeeding: Use during pregnancy or breastfeeding is not recommended, as the medication can pass into breast milk.

Conclusion: Determining if Vyvanse is Right for You

Deciding whether to pursue Vyvanse treatment is a collaborative effort between a patient and their healthcare provider. While a diagnosis of ADHD or moderate to severe BED is a prerequisite, it is not the only factor. A comprehensive medical and psychiatric evaluation, including a review of personal and family history, is essential for patient safety. Any patient considering Vyvanse should be prepared to openly discuss their symptoms, health history, and any concerns with a qualified professional. Ultimately, the provider's assessment, based on established diagnostic criteria and safety guidelines, will determine if Vyvanse is a medically appropriate option for managing your specific condition.

Learn more about Vyvanse and other medications from the official prescribing information on the FDA website.

Frequently Asked Questions

The first step is to schedule an appointment with a licensed healthcare provider to discuss your symptoms and undergo a comprehensive medical and psychological evaluation to determine if you meet the diagnostic criteria for ADHD or moderate to severe Binge Eating Disorder.

No, Vyvanse is not indicated or recommended for weight loss. Its safety and effectiveness for treating obesity have not been established by the FDA.

Vyvanse can be prescribed by various licensed healthcare providers who have a DEA registration to prescribe controlled substances. This includes primary care physicians, psychiatrists, nurse practitioners, and physician assistants.

Yes, a healthcare provider will conduct a careful history and physical exam to assess for cardiac disease before starting Vyvanse. Blood pressure and heart rate will also be monitored throughout treatment.

Yes, it is possible to get a Vyvanse prescription online through a telehealth provider, provided they are properly licensed and registered with the DEA. The provider must still conduct a thorough evaluation to ensure the prescription is medically necessary.

Yes, certain conditions can prevent you from taking Vyvanse. These include a history of structural heart problems, severe kidney impairment, advanced arteriosclerosis, or symptomatic cardiovascular disease.

Vyvanse has a high potential for abuse and dependence. If you have a history of substance abuse, your healthcare provider will likely not prescribe it and will discuss alternative treatment options.

References

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8

Medical Disclaimer

This content is for informational purposes only and should not replace professional medical advice.